MX2021014000A - Formulaciones oftalmicas topicas de liposomas cargados con acetonido de triamcinolona para la prevencion del engrosamiento macular y sus resultados visuales asociados despues de la cirugia del cristalino. - Google Patents

Formulaciones oftalmicas topicas de liposomas cargados con acetonido de triamcinolona para la prevencion del engrosamiento macular y sus resultados visuales asociados despues de la cirugia del cristalino.

Info

Publication number
MX2021014000A
MX2021014000A MX2021014000A MX2021014000A MX2021014000A MX 2021014000 A MX2021014000 A MX 2021014000A MX 2021014000 A MX2021014000 A MX 2021014000A MX 2021014000 A MX2021014000 A MX 2021014000A MX 2021014000 A MX2021014000 A MX 2021014000A
Authority
MX
Mexico
Prior art keywords
prevention
triamcinolone acetonide
ophthalmic formulations
topical ophthalmic
associated visual
Prior art date
Application number
MX2021014000A
Other languages
English (en)
Spanish (es)
Inventor
Jane H Hsiao
Arturo Santos
Jose Navarro
Juan C Altamirano
Alejandro Gonzalez
Original Assignee
Opko Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/426,712 external-priority patent/US11458199B2/en
Application filed by Opko Pharmaceuticals Llc filed Critical Opko Pharmaceuticals Llc
Publication of MX2021014000A publication Critical patent/MX2021014000A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MX2021014000A 2019-05-16 2020-05-05 Formulaciones oftalmicas topicas de liposomas cargados con acetonido de triamcinolona para la prevencion del engrosamiento macular y sus resultados visuales asociados despues de la cirugia del cristalino. MX2021014000A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848907P 2019-05-16 2019-05-16
US16/426,712 US11458199B2 (en) 2012-08-21 2019-05-30 Liposome formulations
PCT/US2020/031417 WO2020231670A1 (fr) 2019-05-16 2020-05-05 Formulations ophtalmiques topiques contenant des liposomes chargés d'acétonide de triamcinolone pour la prévention de l'épaississement maculaire et de ses résultats visuels associés après une chirurgie du cristallin

Publications (1)

Publication Number Publication Date
MX2021014000A true MX2021014000A (es) 2021-12-10

Family

ID=70779973

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014000A MX2021014000A (es) 2019-05-16 2020-05-05 Formulaciones oftalmicas topicas de liposomas cargados con acetonido de triamcinolona para la prevencion del engrosamiento macular y sus resultados visuales asociados despues de la cirugia del cristalino.

Country Status (3)

Country Link
EP (1) EP3968949A1 (fr)
MX (1) MX2021014000A (fr)
WO (1) WO2020231670A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4164593A1 (fr) * 2020-06-15 2023-04-19 OPKO Pharmaceuticals, LLC Formulations ophtalmiques topiques à base de liposomes chargés d'acétonide de triamcinolone en tant que thérapie primaire pour un ?dème maculaire secondaire à une occlusion de la veine rétinienne ramifiée
US12029729B2 (en) 2021-07-23 2024-07-09 Somerset Therapeutics, Llc Chelated, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof
US11793789B2 (en) 2021-07-23 2023-10-24 Somerset Therapeutics, Llc Treatment of ophthalmological conditions using buffer-free ophthalmological compositions of ketorolac and phenylephrine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015003658B1 (pt) * 2012-08-21 2022-09-27 Opko Pharmaceuticals, Llc Formulação oftálmica, uso da dita formulação no tratamento de doença oftálmica do segmento posterior, formulação de lipossomas e suspensão oftálmica lipossomal
CN105997872B (zh) * 2016-07-08 2019-02-19 河南省立眼科医院 一种含有泊沙康唑的眼用纳米胶束抗真菌溶液

Also Published As

Publication number Publication date
WO2020231670A1 (fr) 2020-11-19
WO2020231670A9 (fr) 2021-01-07
EP3968949A1 (fr) 2022-03-23

Similar Documents

Publication Publication Date Title
MX2021014000A (es) Formulaciones oftalmicas topicas de liposomas cargados con acetonido de triamcinolona para la prevencion del engrosamiento macular y sus resultados visuales asociados despues de la cirugia del cristalino.
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
EP4248971A3 (fr) Compositions et méthodes d'utilisation de nintédanib pour le traitement de maladies oculaires à néovascularisation anormale
AU2018218696B2 (en) Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid
EP3643723A4 (fr) Nouveau peptide et composition pharmaceutique pour le traitement de maladies oculaires comprenant ledit nouveau peptide en tant que principe actif
IL273531A (en) Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
EP3902525A4 (fr) Compositions pharmaceutiques ophtalmiques et procédés de traitement d'une maladie de surface oculaire
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
IL287802A (en) Preparations and methods for the treatment of eye diseases
TN2019000112A1 (en) Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma
MX338323B (es) Formulacion topica oftalmica de peptidos.
MX2021005077A (es) Peptidos y composiciones farmaceuticas para tratar enfermedades oculares.
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
EP3813794A4 (fr) Compositions ophtalmiques et méthodes de traitement de troubles oculaires
EP3746106A4 (fr) Inhibiteurs d'endopeptidase neutre (nep) et d'endopeptidase humaine soluble (hsep) destinés à la prophylaxie et au traitement de maladies oculaires
MX2021015781A (es) Formulacion de base lipidica de uso topico oftalmico, que contiene extracto de arandano azul como componente principal para hacer mas eficiente la penetracion y biodisponibilidad de sus bioactivos en tejidos blancos intraoculares en seres humanos.
EP3860592A4 (fr) Compositions ophtalmiques et méthodes de traitement de maladies oculaires et de maladies cutanées
MX2022006523A (es) Composicion que comprende budesonida para uso oftalmico.
ZA202100656B (en) Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases
EP4268834A4 (fr) Composition pour la prévention ou le traitement de maladies oculaires comprenant des vésicules extracellulaires issues de micrococcus lutéus
EP3787609A4 (fr) Formulation de gouttes oculaires et méthode d'administration prolongée de médicament à la rétine
EP4017500A4 (fr) Compositions et méthodes de traitement de la blépharite antérieure et de la blépharite postérieure
MX2022009136A (es) Composicion farmaceutica oftalmica y uso de la misma.
MX2022015836A (es) Composiciones y metodos para el cuidado ocular posoperatorio.